| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Agreement to Distribute Electrochemical Blood Glucose Monitoring System WALTHAM, Mass., Oct. 22, 1996-- Selfcare, Inc. (AMEX: SLF) announced that it has entered into a distribution agreement with LifeScan, Inc., a subsidiary of Johnson & Johnson (NYSE: JNJ), pursuant to which LifeScan will distribute an advanced version of Selfcare's proprietary electrochemical blood glucose monitoring system. As previously announced, Selfcare recently received FDA clearance for a prior version of the system. The advanced version must receive FDA clearance before sales can commence in the United States. As contemplated by the November 10, 1995 agreements between Selfcare and LifeScan, in connection with entering into the distribution agreement LifeScan has paid Selfcare a $7 million success fee, and an affiliate of LifeScan has converted its existing loans of approximately $13.7 million into 201,622 shares of Selfcare common stock. In addition, the LifeScan affiliate will also receive, for no additional consideration, further shares equal to 5% of all common stock issued by Selfcare pursuant to options and warrants that were outstanding as of November 10, 1995. The company estimates that the LifeScan affiliate will ultimately receive approximately 278,800 additional shares. Selfcare, with facilities in Waltham, Massachusetts, Inverness, Scotland, Galway, Ireland, and Munich, Germany, is engaged in the development, manufacture and marketing of self-test diagnostic products for the diabetes, women's health and infectious disease markets.
|